Avalon Biomedical (Management) Limited (“ABM” or together with its subsidiaries, the “Group”) is pleased to announce that the Photonics’ KangaLite Phototherapy System has granted fast-track status for Class II medical device by the National Provincial Medical Products Administration (NMPA) on April 9, 2019.

NMPA issued the Pilot Program for Market Authorization Holder (MAH) system on May 4, 2018, to accelerate the marketing process of domestic medical devices and the Group is excited about the potential of bringing the KangaLite device to market as soon as possible.